Post by Symeres

What if the ADME risk that derails your program in six months could have been caught in six weeks? When issues surface after timelines, budgets, and development strategies are already locked in, programs slow down. And in a landscape where competitors are moving faster than ever and funding windows are tighter, falling behind isn't just frustrating — it's costly. Any of these issues feel familiar? • Poor metabolic stability • Drug-drug interactions • Toxicity signals • Low permeability So how do you avoid them? 👇 Running ADME studies when the data can still shape decisions, not just confirm them after the fact. Early ADME insight helps teams: 🔬 Identify liabilities before major investment ⚡ Improve decision-making during design–make–test cycles 🧠 Balance potency with developability earlier 📈 Reduce costly downstream rework and delays See how early ADME-Tox insight can shape your next program: https://lnkd.in/emdvBF_q